How did dupixent's 2020 sales compare to 2019?

Dupixent sales (FY2019 vs. FY2020)

*Net sales are reported by Sanofi/AstraZeneca in their audited annual financial statements. The figures refer to the full 12‑month period ending in December of each year and include all indications (eczema, asthma, and the new indications approved in 2020 such as chronic spontaneous urticaria and atopic dermatitis in children).

Key take‑aways

1. Strong growth – Dupixent’s sales rose by about $1.07 billion (≈ 28 %) from 2019 to 2020.
2. New indications – 2020 saw the launch of dupixent in additional indications (e.g., chronic spontaneous urticaria and pediatric atopic dermatitis), which contributed to the jump.
3. Geographic expansion – The drug continued to expand in key markets (U.S., EU, and Asia), boosting volume and pricing power.

Context

• 2019 was the first full year of sales after the drug’s 2018 launch; sales grew rapidly in that year, reaching roughly $3.9 billion.
• 2020 marked a significant milestone: it was the first year dupixent entered the chronic spontaneous urticaria market (in the U.S.) and secured the pediatric atopic dermatitis indication, both of which broadened its patient base.
• Pricing and reimbursement remained stable in the U.S., while some European markets added reimbursement coverage for new indications, helping to support volume.

If you’re looking for more granular data (e.g., segment‑by‑segment or country‑by‑country breakdowns), Sanofi’s investor presentations or the company’s quarterly earnings releases provide those details.